December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ:NAMS)

32.99 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NewAmsterdam Pharma Company N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
What Analysts Are Saying About NewAmsterdam Pharma Co Stock ↗
 
Via Benzinga
News headline image
Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib ↗
NewAmsterdam shared new Phase 3 data showing obicetrapib reduced LDL-C by 33% and impacted Alzheimer's biomarkers ahead of July 2025 presentation. 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Monday's pre-market session. ↗
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
7 Analysts Have This To Say About NewAmsterdam Pharma ↗
 
Via Benzinga
News headline image
Deep Dive Into NewAmsterdam Pharma Stock: Analyst Perspectives (8 Ratings) ↗
 
Via Benzinga
News headline image
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
Where NewAmsterdam Pharma Stands With Analysts ↗
 
Via Benzinga
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress
Presentations include new data from BROADWAY and TANDEM Phase 3 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkers 
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
The Analyst Verdict: NewAmsterdam Pharma Co In The Eyes Of 6 Experts ↗
 
Via Benzinga
News headline image
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol? ↗
The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9. 
Via Investor's Business Daily
News headline image
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
Why ZoomInfo Technologies Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio? ↗
These 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN. 
Via Benzinga
News headline image
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.